Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial.

Petrou S, Dakin H, Abangma G, Benge S, Williamson I.

Value Health. 2010 Aug;13(5):543-51. doi: 10.1111/j.1524-4733.2010.00711.x. Epub 2010 Mar 22.

2.

A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care.

Williamson I, Benge S, Barton S, Petrou S, Letley L, Fasey N, Abangma G, Dakin H, Little P.

Health Technol Assess. 2009 Aug;13(37):1-144. doi: 10.3310/hta13370.

3.

Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial.

Williamson I, Benge S, Barton S, Petrou S, Letley L, Fasey N, Haggard M, Little P.

BMJ. 2009 Dec 16;339:b4984. doi: 10.1136/bmj.b4984.

4.

A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion.

Bhargava R, Chakravarti A.

Am J Otolaryngol. 2014 Nov-Dec;35(6):766-70. doi: 10.1016/j.amjoto.2014.06.006. Epub 2014 Jun 20.

PMID:
25151658
5.

Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children.

Butler CC, Van Der Voort JH.

Cochrane Database Syst Rev. 2002;(4):CD001935. Review. Update in: Cochrane Database Syst Rev. 2006;(3):CD001935.

PMID:
12519563
6.

The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy.

Cengel S, Akyol MU.

Int J Pediatr Otorhinolaryngol. 2006 Apr;70(4):639-45. Epub 2005 Sep 16.

PMID:
16169093
7.

Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire.

Dakin H, Petrou S, Haggard M, Benge S, Williamson I.

Qual Life Res. 2010 Feb;19(1):65-80. doi: 10.1007/s11136-009-9558-z. Epub 2009 Nov 26.

PMID:
19941078
8.

Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial.

Waldron CA, Thomas-Jones E, Cannings-John R, Hood K, Powell C, Roberts A, Tomkinson A, Fitzsimmons D, Gal M, Harris D, Shepherd V, Butler CC, Francis N.

Trials. 2016 Mar 1;17(1):115. doi: 10.1186/s13063-016-1236-1.

9.

Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children.

Simpson SA, Lewis R, van der Voort J, Butler CC.

Cochrane Database Syst Rev. 2011 May 11;(5):CD001935. doi: 10.1002/14651858.CD001935.pub3. Review.

PMID:
21563132
10.

A model-based cost-effectiveness analysis of a grommets-led care pathway for children with cleft palate affected by otitis media with effusion.

Mohiuddin S, Payne K, Fenwick E, O'Brien K, Bruce I.

Eur J Health Econ. 2015 Jul;16(6):573-87. doi: 10.1007/s10198-014-0610-8. Epub 2014 Jun 7.

PMID:
24906214
11.

Antibiotics for otitis media with effusion in children.

van Zon A, van der Heijden GJ, van Dongen TM, Burton MJ, Schilder AG.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009163. doi: 10.1002/14651858.CD009163.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;(6):CD009163.

PMID:
22972136
12.

Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial.

Wilson EC, Price D, Musgrave SD, Sims EJ, Shepstone L, Murdoch J, Mugford HM, Blyth A, Juniper EF, Ayres JG, Wolfe S, Freeman D, Gilbert RF, Hillyer EV, Harvey I.

Pharmacoeconomics. 2010;28(7):597-608. doi: 10.2165/11537550-000000000-00000.

PMID:
20446755
13.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

14.

BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.

Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, Barnes M, Ford G, Graham L; BoTULS investigators.

Health Technol Assess. 2010 May;14(26):1-113, iii-iv. doi: 10.3310/hta14260.

15.

Economic evaluation of surgical insertion of ventilation tubes for the management of persistent bilateral otitis media with effusion in children.

Mohiuddin S, Schilder A, Bruce I.

BMC Health Serv Res. 2014 Jun 13;14:253. doi: 10.1186/1472-6963-14-253.

16.

Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children.

Thomas CL, Simpson S, Butler CC, van der Voort JH.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001935. Review. Update in: Cochrane Database Syst Rev. 2011;(5):CD001935.

PMID:
16855980
17.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

18.

Systematic review and meta-analysis of randomized controlled trials on the role of mometasone in adenoid hypertrophy in children.

Chohan A, Lal A, Chohan K, Chakravarti A, Gomber S.

Int J Pediatr Otorhinolaryngol. 2015 Oct;79(10):1599-608. doi: 10.1016/j.ijporl.2015.07.009. Epub 2015 Jul 13. Review.

PMID:
26235732
19.

Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children.

Butler CC, van Der Voort JH.

Cochrane Database Syst Rev. 2000;(4):CD001935. Review. Update in: Cochrane Database Syst Rev. 2002;(4):CD001935.

PMID:
11034736
20.

Intranasal beclomethasone as an adjunct to treatment of chronic middle ear effusion.

Tracy JM, Demain JG, Hoffman KM, Goetz DW.

Ann Allergy Asthma Immunol. 1998 Feb;80(2):198-206.

PMID:
9494455

Supplemental Content

Support Center